The Search for Genomic Biomarkers of Response to Immunotherapy in Ovarian Cancer

Authors:
Publisher website
Google Scholar
Abstract
Summary: Immune checkpoint blockade has been ineffective in ovarian cancer, and there is an ongoing effort to identify biomarkers of therapeutic benefit. Despite promising preclinical data, a substudy of the IMagyn050 trial found that patients with homologous recombination deficient tumors did not have improved progression-free survival with the addition of the PD-L1 inhibitor atezolizumab. See related article by Landen et al., p. 1698
Funding Information
  • National Institutes of Health (P30 CA008748)
  • National Institutes of Health (T32-CA009207)

This publication has 16 references indexed in Scilit: